IRIS
PASSALACQUA, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 60.136
AS - Asia 5.050
NA - Nord America 1.598
SA - Sud America 420
AF - Africa 83
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 67.299
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 59.124
SG - Singapore 2.385
US - Stati Uniti d'America 1.498
CN - Cina 1.296
VN - Vietnam 788
FR - Francia 495
BR - Brasile 264
FI - Finlandia 197
HK - Hong Kong 173
DE - Germania 101
AR - Argentina 70
JP - Giappone 66
MX - Messico 64
IQ - Iraq 48
GB - Regno Unito 46
BD - Bangladesh 45
IN - India 37
NL - Olanda 30
CH - Svizzera 27
ID - Indonesia 25
PH - Filippine 22
TH - Thailandia 21
EC - Ecuador 19
JO - Giordania 17
RU - Federazione Russa 17
ZA - Sudafrica 17
CA - Canada 16
EG - Egitto 16
ES - Italia 16
TR - Turchia 16
VE - Venezuela 16
PK - Pakistan 15
CO - Colombia 14
IE - Irlanda 14
KR - Corea 14
MA - Marocco 12
UA - Ucraina 11
CL - Cile 10
PE - Perù 10
SA - Arabia Saudita 9
TW - Taiwan 9
AT - Austria 8
AZ - Azerbaigian 8
DZ - Algeria 8
UY - Uruguay 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
NP - Nepal 7
PT - Portogallo 7
KZ - Kazakistan 6
LT - Lituania 6
MY - Malesia 6
BO - Bolivia 5
KE - Kenya 5
RO - Romania 5
DO - Repubblica Dominicana 4
HN - Honduras 4
PL - Polonia 4
PY - Paraguay 4
BE - Belgio 3
BG - Bulgaria 3
CY - Cipro 3
KG - Kirghizistan 3
MD - Moldavia 3
NE - Niger 3
OM - Oman 3
PA - Panama 3
SE - Svezia 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AL - Albania 2
BF - Burkina Faso 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
HU - Ungheria 2
LB - Libano 2
LV - Lettonia 2
MM - Myanmar 2
NA - Namibia 2
NG - Nigeria 2
PS - Palestinian Territory 2
SI - Slovenia 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
GA - Gabon 1
GH - Ghana 1
GT - Guatemala 1
IL - Israele 1
IR - Iran 1
Totale 67.286
Salva come PNG Salva come JPEG
Città #
Genova 41.035
Genoa 10.362
Rapallo 4.496
Vado Ligure 2.986
Singapore 1.110
San Jose 781
Lauterbourg 481
Ho Chi Minh City 211
Helsinki 191
Hanoi 185
Hong Kong 164
Ashburn 163
New York 95
Frankfurt am Main 81
Beijing 80
Council Bluffs 77
Bordighera 71
Santa Clara 68
Tokyo 60
Mexico City 39
Da Nang 36
Haiphong 36
Tianjin 35
Zurich 27
Los Angeles 24
São Paulo 22
Baghdad 19
City of London 16
Amsterdam 15
Amman 14
Biên Hòa 14
Dublin 14
Nuremberg 14
Bangkok 13
Des Moines 13
Milan 13
Orem 13
Shanghai 13
Can Tho 12
Cardiff 11
Dallas 11
Guangzhou 11
Belo Horizonte 10
Chicago 10
Jakarta 10
Turin 10
Rome 9
Hải Dương 8
Montevideo 8
Naples 8
Nha Trang 8
Quito 8
Rio de Janeiro 8
Baku 7
Bologna 7
Dhaka 7
Shenzhen 7
Tashkent 7
Agawam 6
Lima 6
Porto Alegre 6
Quận Ba 6
Thái Bình 6
Buenos Aires 5
Cairo 5
Cape Town 5
East Gwillimbury 5
Guayaquil 5
Hưng Yên 5
Kuala Lumpur 5
Long Xuyen 5
Madrid 5
Manchester 5
Quảng Ngãi 5
San Juan 5
Santiago 5
Tân Tiến 5
Vienna 5
Vĩnh Long 5
Ân Thi 5
Bergamo 4
Brooklyn 4
Bắc Ninh 4
Bến Tre 4
Caracas 4
Casablanca 4
Karachi 4
Kyiv 4
Lappeenranta 4
London 4
Moscow 4
Mosul 4
Nairobi 4
Ninh Bình 4
Oeiras 4
Paris 4
Riyadh 4
San Miguel de Tucumán 4
Thái Nguyên 4
Toronto 4
Totale 63.459
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 321
Immunoterapia specifica: una possibilità di gestione del rischio professionale da allergia al veleno di imenotteri 239
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 207
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. 204
Adhesion molecules in allergy. 203
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 202
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early and late phase reactions after allergen-specific challenge. 200
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. 198
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 195
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 191
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. 190
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. 189
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 187
Local Side Effects of Sublingual and Oral Immunotherapy 184
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 184
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 184
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. 181
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision 180
A survey of clinical features of allergic rhinitis in adults. 179
Personalized medicine in allergy 179
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 179
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 177
Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. 174
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. 174
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. 174
A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020 170
Fibrous invasive (Riedel's) thyroiditis with critical response to steroid treatment. 168
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. 168
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. 168
Catching allergy by a simple questionnaire 168
Nasal cytology: Methodology with application to clinical practice and research 167
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. 166
Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. 166
A critical appraisal on AIT in childhood asthma 166
Basi Patogenetiche ed anatomopatologiche della flogosi allergica nell’asma bronchiale 165
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 165
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma 164
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. 163
Current insights in allergen immunotherapy 163
Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial 163
30 Years Of Sublingual Immunotherapy 163
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 163
Aerobiologic diagnosis of brassicaceae-induced asthma. 161
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 161
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 161
CD4(+)IL-13(+) cells in peripheral blood well correlates with the severity of atopic dermatitis in children. 160
Umeclidinium for the treatment of uncontrolled asthma 159
A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics 159
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco. 159
Allergy and the bone: unexpected relationships. 158
A prospective italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. 158
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. 157
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) 157
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. 157
The safety of monoclonal antibodies in asthma 156
Serum cytotoxic T lymphocyte-associated antigen 4 in hymenoptera venom allergy and its modulation by specific immunotherapy 156
Allergenius, an expert system for the interpretation of allergen microarray results 155
Latex-jujube cross-reactivity: case report and immunological study. 154
Allergen-specific nasal challenge: response kinetics of clinical and inflammatory events to rechallenge. 154
Continuous versus on demand treatment with cetirizine for allergic rhinitis. 154
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 154
The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. 153
Molecular diagnosis and precision medicine in allergy management 152
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. 151
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study 151
When allergic rhinitis is not only allergic. 151
The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years 150
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. 150
Appropriateness in allergic respiratory diseases health care in Italy: Definitions and organizational aspects 150
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 150
[Anti-leukotriene agents: rationale for and prospects of use]. 150
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum ctla-4 and IL-10. 149
Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. 148
Sublingual immunotherapy. 148
Antihistamines in atopic dermatitis. 148
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. 148
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. 148
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. 147
Hymenoptera venom allergy in outdoor workers: Occupational exposure, clinical features and effects of allergen immunotherapy 147
Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure rhinitis due to house dust mite over a 5-year period 147
Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. 146
Sublingual and oral immunotherapy. 146
The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. 146
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle 146
The classification of allergic rhinitis and its cytological correlate. 146
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 146
Antihistamines in the treatment of bronchial asthma. Present knowledge and future perspectives 145
An update on the asthma-rhinitis link. 145
Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. 145
Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. 145
Sublingual immunotherapy: other indications. 145
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation 145
Sublingual immunotherapy: World Allergy Organization position paper 2013 update 145
2019 ARIA Care pathways for allergen immunotherapy 145
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper 144
The asthma-rhinitis association: between the clinical hypothesis and the scientific theory. 144
Is alternative medicine acceptable in allergology? 144
Prevalence of allergy to Cypress. 144
Executive summary of European Task Force document on diagnostic tools in rhinology. 144
Will sublingual immunotherapy offer benefit for asthma? 144
Totale 16.419
Salva come PNG Salva come JPEG
Categoria #
all - tutte 207.857
article - articoli 206.746
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.111
Totale 415.714
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.199 0 0 0 0 0 0 0 0 0 470 273 456
2021/20226.596 152 387 560 940 117 560 551 1.378 276 571 310 794
2022/20235.473 598 221 30 477 836 1.112 52 508 1.078 96 388 77
2023/20242.361 177 419 52 195 233 362 122 106 129 47 162 357
2024/20256.939 101 700 275 440 1.060 682 659 861 267 382 575 937
2025/202611.569 1.237 385 854 945 1.457 1.761 2.435 594 954 947 0 0
Totale 68.046